Emergent BioSolutions Inc. EBS 深 沪
等待开盘 10-17 09:30:00 美东时间
6.38
-0.800
-11.14%
华盛通- 最 高6.73
- 今 开6.64
- 成交量 223.71万股
- 最 低 6.1505
- 昨 收 7.18
- 总市值 3.27亿
- 52周最高 14.06
- 市盈率 静 6.88
- 换手率 4.36%
- 52周最低 4.36
- 委 比 50.00%
- 总股本 5127.33万
- 历史最高 137.61
- 量 比 2.95
- 振 幅 8.07%
- 历史最低 1.42
- 每 手 1
- 风险率 2.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Emergent BioSolutions shares are trading lower. The company announced its CFO Richard Lindahl will retire, with Treasurer Frank Vargo set to serve as interim CFO effective January 1, 2027.
Emergent BioSolutions shares are trading lower. The company announced its CFO Richard Lindahl will retire, with Treasurer Frank Vargo set to serve as interim CFO effective January 1, 2027.
今天 02:15
Emergent BioSolutions Announces CFO Transition Amid Transformation
Emergent Biosolutions ( ($EBS) ) has shared an update. Emergent BioSolutions an...
10-16 20:25
Emergent BioSolutions restructuring includes 90 job cuts
Emergent BioSolutions (EBS) is undergoing a restructuring that aims for annualized savings of ~$40M but also includes 90 layoffs. The company will shutter two Maryland laboratories, sell an unutilized...
09-15 05:26
Emergent Biosolutions Highlights Global Public Health Countermeasures
Emergent Biosolutions ( ($EBS) ) just unveiled an update. On September 14, 2026...
09-15 04:36
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $10 price target.
09-09 19:16
Emergent BioSolutions Receives Canada's Offer To Provide NARCAN Nasal Spray, Effective Oct. 1 Through September 2029
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option to e...
08-31 19:58
JP Morgan Reinstates Underweight on Emergent BioSolutions
JP Morgan analyst Jessica Fye reinstates Emergent BioSolutions (NYSE:EBS) with a Underweight.
08-22 03:18
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
Emergent BioSolutions shares are trading lower after the company lowered its FY2026 sales guidance.
Emergent BioSolutions shares are trading lower after the company lowered its FY2026 sales guidance.
08-06 04:58
